Amundi Private Equity Funds
91-93 boulevard Pasteur, Paris, Ile-de-France, 75015, France
Overview
Amundi Private Equity Funds, an Amundi asset management subsidiary, specialises in private equity and unlisted infrastructure investments. Combining a wealth of expertise in all aspects of asset management built up over more than 10 years, Amundi provides both institutional and individual investors with a wide spectrum of investment opportunities, ranging from direct fund investments in unlisted French and foreign companies to dedicated mandates and funds-of-funds for multi-management private equity and infrastructure investments. With more than 60 professionals based in Paris, Bucharest, Cairo, Casablanca, Tunis and Warsaw, Amundi Private Equity Funds assists companies at all stages of their development, the key objective being to offer fund subscribers yields in line with the best in the industry. At 31 December 2009, French and international subscribers had committed more than €3.7 billion to Amundi Private Equity Funds, making it a leading private equity player. The company owes its solid foundations to its positioning as part of a leading third-party asset management group of companies and to its membership of two international banking groups.
- Total investments
- 6
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Splio
Participated · Equity · Sep 2019
Splio provides a SaaS-based omnichannel marketing platform that combines marketing automation, loyalty marketing and Mobile Wallet Marketing to help marketers acquire, engage, and personalize campaigns across channels. The platform supports both points-based and relationship-based loyalty programs and mobile wallet integrations. Splio serves over 500 brands across eight industries, including The Kooples, FNAC, Le Slip Français, Big Fernand, GiFi, Maty, and Longchamp. The company operates five offices and has 150 employees across Europe and China. Splio intends to use the new funding to accelerate product development and international growth. The company announced an additional €10M funding round to support these plans.
- Genticel
Participated · Equity · Apr 2013
Genticel develops therapeutic vaccines against high‑risk HPV infections. The company’s lead candidate, ProCervix, completed a Phase I clinical study and is moving into Phase II to demonstrate proof of efficacy. Its pipeline also includes a CyaA‑based multivalent HPV vaccine designed to cover additional virus subtypes. Genticel plans to use newly raised funds to advance both HPV vaccine candidates through clinical development. The company is led by founder and CEO Benedikt Timmerman and is based in Paris and Toulouse, France. Genticel, formerly BT Pharma, is a Labège, France-based biopharmaceutical company developing therapeutic immunotherapies targeting HPV-caused cancers. Its proprietary platform is Adenylate Cyclase (CyaA) and its lead candidate is the therapeutic HPV vaccine ProCervix. The company aims to provide a curative vaccine solution that complements existing prophylactic HPV vaccines, with a focus on preventing cervical cancer in HPV-infected women. Genticel secured €13.1m in additional funding to advance clinical development. The proceeds are earmarked to support a "first-in-man" clinical trial of the CyaA platform and a Phase I clinical trial of ProCervix. As part of the financing, Dr Alain Munoz of AGF Private Equity joined the company’s supervisory board.
- Arterial Remodeling Technologies
Participated · Equity · Sep 2010
Arterial Remodeling Technologies develops fully resorbable coronary polymer stents intended to promote natural remodeling of an injured artery after angioplasty. The technology is based on intellectual property originating from the Cleveland Clinic, CNRS (Montpellier) and Descartes University (Paris). The company is based in Noisy le Roi, France. On 21 September 2010 it closed an $8.5M new venture financing round. That financing brought the total capital raised by the company to date to $17M. Investors in the round included existing backers Matignon Technologies and Amundi Private Equity Funds and new partner InnoBio Fund (managed by CDC Entreprises).
- McPhy
Participated · Equity · Jul 2010
McPhy Energy develops and provides a technology for the solid storage of hydrogen in the form of magnesium hydride. The company has created an alternative solution for on-site hydrogen production aimed at industry and the renewable energy sectors. McPhy raised €13.7m in a second round of funding to reinforce its commercial and technical team and to invest in additional production equipment. In January 2009 it previously raised €1.6m from Emertec and Areva. The company is already present in Spain and in Italy and is planning to open offices in Germany, Northern Europe, the Middle East and Japan. The new capital is intended to support its commercialization and expansion of production capabilities.
- Wyplay
Led · Equity · May 2010
WYPLAY SAS, based in Alluach, France, develops and provides connected HDTVs, media center CE devices, HD IPTV boxes, HD set-top boxes and in-home media-HDD products. Its clients include SFR-Vodafone and D-Link. The company closed a €9.0m third financing round led by Amundi Private Equity Funds with participation from existing investors A Plus Finance, Elaia Partners and Sofinnova Partners. Together with two previous investment rounds totaling €14.0m, the new round brings Wyplay’s total funding to €23.0m raised over three years. The new capital will enable the company to expand its offering by adding innovative web services, including an Application Store and the aggregation of hundreds of online TV content providers.